{
  "docId": "019de072-47f9-754b-bd81-b37e2d3aff4a",
  "docSlug": "3579f0f2aa567a18deef7848f39c9b29",
  "documentTitle": "argenx SE | Results Presentation Deck | 17 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 17,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a parallel process flow to compare IV and SC dosing regimens.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-47f9-754b-bd81-b37e2d3aff4a/6",
  "deckHref": "/decks/019de072-47f9-754b-bd81-b37e2d3aff4a",
  "deckJsonHref": "/decks/019de072-47f9-754b-bd81-b37e2d3aff4a.json",
  "deckAnchorHref": "/decks/019de072-47f9-754b-bd81-b37e2d3aff4a#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.2,
        "x": 0.78,
        "y": 0.035
      },
      "kind": "callout",
      "text": "Primary objective: Durable response: sustained platelet count (≥50x10^9/L) in 4/6 visits between weeks 19 and 24",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea073f70-ff3b-431e-ac29-e42b0841a71f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Parallel trial design flow for IV and SC arms",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97dbae8f-6ee3-49fd-8a95-fcb03c6be60a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Topline IV data expected 2Q 2022; topline SC data expected 1Q 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b87995b-33c0-4cc0-82bc-6ea7933280c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "subtitle",
      "text": "Phase 3, multicenter, randomized, double-blind, placebo-controlled trial",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddcb7db7-89d0-4041-b493-55217d209126",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Immune Thrombocytopenia ADVANCE Trials: Two Run in Parallel",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e707d2b5-7d14-4f63-be94-fb5c06de5276",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "1f1125fb-c25f-41eb-a50a-ec000a4963a5",
      "evidence": "The slide depicts a clinical trial workflow with distinct stages and parallel arms.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "9932269f-c8ce-4b89-a9c8-6bb2ab964969",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation highlights VYVGART's benefits and its potential to address unmet needs.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8074f39d-c5c8-49a7-b1a2-34670dd56fb4",
      "evidence": "The presentation implies that not adopting VYVGART would mean missing out on a potentially life-changing treatment option.",
      "position": 0,
      "objective": "What are the consequences of not adopting VYVGART?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}